Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Obesity | Phase 2 | - | - | |
Nonalcoholic Steatohepatitis | Phase 1 | US | 07 Feb 2021 |
NCT04838405 (EASD2024) Manual | Phase 1 | 46 | (hqkwdmehje) = mlzmmiophv hjtiwieotq (nspuppsphj ) View more | Positive | 11 Sep 2024 | ||
(hqkwdmehje) = rlpqueksmw hjtiwieotq (nspuppsphj ) View more | |||||||
Phase 1 | 24 | CT-388 5/5/5/7.5 mg (C6) | (qnksxghqrp) = jkskhlvuic vzwzoreugq (fnaebiyolp ) | Positive | 15 Oct 2023 | ||
CT-388 5/5/8/12 mg (C7) | (qnksxghqrp) = dvpcijncka vzwzoreugq (fnaebiyolp ) | ||||||
Not Applicable | 64 | xseradehty(xttpgdzvrn) = ↓26-28% bnelknwjaj (wdceqrejen ) View more | - | 20 Jun 2023 |